Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 January 2019, 13:33 HKT/SGT
Share:
    

Source: Eisai
Eisai's Notification Regarding Results of Voluntary Retirement Program

TOKYO, Jan 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results as follows:

1. Outline of Voluntary Retirement Program
a) Eligibility Criteria:
Employees 45 or older who have worked at Eisai for five consecutive years or more as of April 1, 2018
b) Effective Date of Retirement:
First round: March 31, 2019; Second round: March 31, 2020;
Third round: March 31, 2021
c) Number of Applicants Sought:
First round: Approximately 100*
d) Application Period:
First round: From December 11, 2018 to December 21, 2018 (may be subject to change based on the application situation). The application periods for the second and third rounds will cover a similar period of time each fiscal year.
e) Preferential Conditions:
A premium will be added to the normal retirement allowance. In addition, applicants will also have the option to receive job-placement assistance.

*The number of applicants sought for the second and third round will be determined in consideration of the outcome of the application situation.

2. Number of Confirmed Applicants / Total Amount of Premium Retirement Payments (First Round)
a) Number of Confirmed Applicants:
300 applicants
b) Total Amount of Premium Retirement Payments:
Approx. 6.6 billion yen

*Judging from the application situation, the application deadline was shortened from December 21, 2018 to December 19, 2018.

3. Impact on Financial Performance
The sum total of premium retirement payments associated with the implementation of the first round of this program will be recorded as expenses in the settlement of accounts for the third quarter of the fiscal year ending March 31, 2019. The full-year consolidated financial results forecasts for the fiscal year ending March 31, 2019 previously announced on November 1, 2018 includes a certain level for these expenses, and based on recent trends in business performance and other factors, there is no change to the full-year consolidated financial results forecasts.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: